20.00k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
|Watchlist||Change today||1-month return||1-year return||Total return|
|The Fight Against COVID19||-8.43%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||156.22||-2.80||-1.76%||4:00 pm GMT-5||6.57M||8.19M||410.65B|
|PFE||Pfizer Inc.||34.39||+0.88||+2.63%||4:02 pm GMT-5||44.24M||40.28M||191.81B|
|ABBV||AbbVie Inc.||106.71||-1.14||-1.06%||4:02 pm GMT-5||6.89M||7.18M||188.44B|
|SNY||Sanofi||45.46||-0.48||-1.04%||4:00 pm GMT-5||1.11M||2.78M||113.67B|
|GSK||GlaxoSmithKline plc||34.24||+0.15||+0.44%||4:00 pm GMT-5||6.30M||5.54M||85.66B|
|GILD||Gilead Sciences, Inc.||62.75||-0.26||-0.41%||4:00 pm GMT-5||6.80M||8.98M||78.85B|
|TAK||Takeda Pharmaceutical Company Limited||17.71||+0.47||+2.73%||4:00 pm GMT-5||5.15M||3.70M||55.71B|
|MRNA||Moderna, Inc.||131.22||-15.59||-10.62%||4:00 pm GMT-5||13.58M||19.09M||52.46B|
|REGN||Regeneron Pharmaceuticals, Inc.||446.73||-8.13||-1.79%||4:00 pm GMT-5||835.94k||1.04M||47.86B|
|BNTX||BioNTech SE||97.25||-7.73||-7.36%||4:00 pm GMT-5||2.13M||2.88M||23.42B|
|NVAX||Novavax, Inc.||183.61||-22.38||-10.86%||4:00 pm GMT-5||4.05M||4.57M||13.56B|
|VIR||Vir Biotechnology, Inc.||41.78||-15.96||-27.64%||4:00 pm GMT-5||7.28M||1.61M||5.34B|
|INO||Inovio Pharmaceuticals, Inc.||9.56||-0.46||-4.59%||4:00 pm GMT-5||15.80M||15.79M||1.96B|
Moderna undercut its 10-week moving average for the second time in two weeks. A continued drop below this key level would trigger a key defensive sell rule.
Karen Colberg, King Arthur Baking Company Co-CEO, joins Yahoo Finance’s Alexis Christoforous to discuss the company’s spike in sales amid the pandemic.
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. While worrisome coronavirus variants identified in Brazil, South Africa, and California have mutations that might help them resist antibody treatments and vaccines, the immune system's T cell responses to the variants are unaffected in recovered patients and in people who have received the Moderna Inc or Pfizer Inc/BioMTech SE vaccines, new data show.